title: Antiplatelet therapy decreases the incidence of erythropoietin-induced hypertension in predialysis patients.
abstract: The observation that antiplatelet therapy may decrease the incidence of Epo-induced hypertension in dialysis patients remains a subject of particular interest. The aim of the present study was to test this hypothesis in patients at the predialysis stage. Predialysis patients with renal anemia were treated with EPO (6000 IU/week) for 6-12 months. Patients were divided into two groups, one of which received antiplatelet therapy and the other did not, and a comparison was made between them with respect to the incidence of EPO-induced hypertension. Logistic regression analysis was used to determine the risk factors for developing hypertension during the EPO therapy. Such predictors included age, gender, antecedent of hypertension, antiplatelet drugs and diabetes mellitus. Overall, 66 patients were enrolled in the study and 18 developed hypertension (27%). Out of the 35 patients not receiving antiplatelet therapy, 15 developed hypertension (43%). In contrast, out of the 31 patients receiving antiplatelet therapy, only 3 (10%) developed hypertension (p=0.003 by Chi square test). Multiple regression analysis showed that the best predictive variables for the development of hypertension were antecedent of hypertension (odds ratio: 0.064, p=0.0118), and use of antiplatelet drugs (odds ratio: 5.081, p=0.0295). The present data provide evidence that antiplatelet therapy may prevent EPO-induced hypertension in predialysis patients. However, the mechanism to explain such an effect still remains to be elucidated.
authors.affiliation: Division of Nephrology, Saiseikai Central Hospital, Tokyo, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Kuriyama
authors.forename: H
authors.initials: H
authors.lastname: Tomonari
authors.forename: T
authors.initials: T
authors.lastname: Hosoya
mesh_terms: D000328:Adult; D000368:Aged; D000740:Anemia / Q000097:blood / Q000188:drug therapy / Q000209:etiology; D004109:Dilazep / Q000627:therapeutic use; D004176:Dipyridamole / Q000627:therapeutic use; D004921:Erythropoietin / Q000009:adverse effects*; D005260:Female; D006400:Hematocrit; D006801:Humans; D006973:Hypertension / Q000209:etiology / Q000517:prevention & control*; D007674:Kidney Diseases / Q000150:complications / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011994:Recombinant Proteins; D006435:Renal Dialysis; D012307:Risk Factors
chemical_list: D010975:Platelet Aggregation Inhibitors; D011994:Recombinant Proteins; D004921:Erythropoietin; D004176:Dipyridamole; D004109:Dilazep